Short answer
AGIOS PHARMACEUTICALS, INC. (AGIO) filed an 8-K current report with the SEC on April 29, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q1 2026 results for quarter ended March 31, 2026, with business highlights.
AGIOS PHARMACEUTICALS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 results for quarter ended March 31, 2026, with business highlights
- Full financial details and management commentary in Exhibit 99.1 press release
- Information furnished under Item 2.02, limiting direct Section 18 liability♀♀♀♀♀♀
Item EX-99.1 · Exhibit EX-99.1
- Q1 2026 product revenue $20.7M, up from $8.7M, signaling accelerating mitapivat commercialization
- AQVESME launch produced 242 thalassemia prescriptions by March 31, establishing early U.S. demand momentum
- Net loss widened to $99.1M from $89.3M as R&D reached $81.1M and SG&A $48.3M
- Sickle-cell sNDA planned for Q2 2026 under accelerated approval, potentially expanding mitapivat’s addressable market
- $1.0B liquidity supports commercialization and pipeline execution, with tebapivat Phase 2 readouts expected in 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other AGIOS PHARMACEUTICALS, INC. 8-K filings
Get the next AGIO 8-K as it lands
Follow AGIO for push alerts, or ask the research agent what this filing means.